Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439578 | 1.00 | MAOB (0.41) | MAOBMAOASLC1A5GRM4CHEK1 | |
| SCHEMBL16534885 | 0.82 | MAOB (0.50) | MAOBMAOASLC1A5CHEK1MCL1 | |
| SCHEMBL3951343 | 0.80 | AAK1 (0.34) | MAOBMAOALMNABACE1NOS3 | |
| SCHEMBL30475151 | 0.78 | MAOB (0.61) | MAOBMAOASLC1A5CHEK1MCL1 | |
| SCHEMBL1395661 | 0.78 | MAOB (0.61) | MAOBMAOASLC1A5CHEK1MCL1 | |
| SCHEMBL28628169 | 0.78 | CYP2A6 (0.42) | MAOBMAOASLC1A5CHEK1MCL1 | |
| SCHEMBL28628069 | 0.78 | CYP2A6 (0.42) | MAOBMAOASLC1A5CHEK1MCL1 | |
| SCHEMBL16956612 | 0.77 | CYP2A6 (0.30) | — | |
| SCHEMBL31310581 | 0.76 | MAOB (0.44) | MAOBMAOASLC1A5CHEK1MCL1 | |
| SCHEMBL1914246 | 0.76 | GRM4 (0.38) | GRM4DYRK1ATTRALBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2025073270-A1 | BIPHENYL TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 海南因瑞生物医药科技有限公司 | 2025-04-10 | — | — | WO | disclosed |
| WO-2025056068-A1 | BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海济煜医药科技有限公司 | 2025-03-20 | — | — | WO | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2025021182-A1 | CYP11A1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-01-30 | — | — | WO | disclosed |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-1776100-A2 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | NEW YORK UNIVERSITY (US) | 2007-04-25 | — | — | EP | disclosed |
| CN-1894225-A | (3, 4-disubstituted) propanoates as sphingosine 1-phosphate (endothelial differentiation gene) receptor agonists | MERCK & CO INC (US) | 2007-01-10 | — | — | CN | disclosed |
| EP-1697333-A1 | (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050209334-A1 | method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors. | NEW YORK UNIVERSITY (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005070024-A2 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | NEW YORK UNIVERSITY (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005058848-A1 | (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-5358663-A | Liquid crystals | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'3 S GOVERNMENT OF U.K. OF GT. BRITAIN AND N. IRELAND (GB) | 1994-10-25 | — | — | US | disclosed |
| EP-0395666-B1 | LATERALLY CYANO- AND FLUORO-SUBSTITUTED TERPHENYLS | SECR DEFENCE BRIT (GB) | 1994-05-04 | — | — | EP | disclosed |
| EP-0395666-A1 | LATERALLY CYANO- AND FLUORO-SUBSTITUTED TERPHENYLS. | SECR DEFENCE BRIT (GB) | 1990-11-07 | — | — | EP | disclosed |
| WO-1989003821-A1 | LATERALLY CYANO- AND FLUORO-SUBSTITUTED TERPHENYLS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) | 1989-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209334-A1 | method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors. | AHR, TYR, CYP4X1 | MAOB 235/4885MAOA 175/4885SLC1A5 1251/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | MAOB 1164/4885MAOA 1774/4885SLC1A5 210/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | MAOB 4372/4885MAOA 4530/4885SLC1A5 3988/4885 |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | MAOB 51/4885MAOA 75/4885SLC1A5 1913/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | MAOB 289/4885MAOA 397/4885SLC1A5 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.